Kidney diseases (Basel, Switzerland) · 2025
How to Enhance Kidney Donation around the World: A Summary of Expert Opinions from the 5th International Congress of Chinese Nephrologists.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Philip K T, Lau Lik Fung Sam, Chow Kai-Ming, Choo Jason C J, Hooi Lai Seong, Lee Ming Che, Lim Wai Hon, Pei York, Tam Frederick Wai-Keung, Yeung Melissa Y, Tang Simon Yiu Hang, Tian Na, Chen Jianghua
Аннотация
PURPOSE: The formation of biofilms hinders direct contact between antibiotics and bacteria, reducing the efficacy of antibiotic therapy and presenting a substantial obstacle to the treatment of chronic osteomyelitis. To address this problem, we successfully constructed a chemically and structurally robust vancomycin-copper-tannic acid (Van@CuTA) antibiotic sustained-release system via a simple synthetic method, to target bacteria and inhibit biofilm formation.
METHODS: Tannic acid (TA), copper ions (Cu2+), and vancomycin hydrochloride (Van) were mixed and stirred at a low temperature to afford Van@CuTA nanospheres. Their antibacterial activity was evaluated against methicillin-resistant S. aureus (MRSA) using the Oxford cup method and live/dead bacterial staining. Their anti-biofilm activity was assessed via FE-SEM observations. Cell viability was assessed via MTT assay and osteogenic activity was detected via Western blotting (WB) and alkaline phosphatase (ALP) staining after co-culture with MG-63 cells. In vivo tibia-induced osteomyelitis model in rabbits was conducted to further validate the efficacy of Van@CuTA in treating osteomyelitis.
RESULTS: The developed nanospheres exhibited drug release properties, with TA being released from the carrier and inhibiting the formation of bacterial biofilms. In vivo experiments demonstrated inhibition of MRSA biofilm formation through the encapsulation of TA within fibrin and its sustained release, followed by the sequential release of Van and Cu2⁺ to directly eradicate MRSA. Moreover, Van@CuTA effectively promoted cell proliferation and bone formation. Van@CuTA is a multifunctional system that integrates biofilm targeting, drug release, antimicrobial activity, and cuproptosis-like bacterial death.
CONCLUSION: This study offers a novel and promising strategy for the development of antimicrobial agents to combat MRSA-induced chronic osteomyelitis.
METHODS: Tannic acid (TA), copper ions (Cu2+), and vancomycin hydrochloride (Van) were mixed and stirred at a low temperature to afford Van@CuTA nanospheres. Their antibacterial activity was evaluated against methicillin-resistant S. aureus (MRSA) using the Oxford cup method and live/dead bacterial staining. Their anti-biofilm activity was assessed via FE-SEM observations. Cell viability was assessed via MTT assay and osteogenic activity was detected via Western blotting (WB) and alkaline phosphatase (ALP) staining after co-culture with MG-63 cells. In vivo tibia-induced osteomyelitis model in rabbits was conducted to further validate the efficacy of Van@CuTA in treating osteomyelitis.
RESULTS: The developed nanospheres exhibited drug release properties, with TA being released from the carrier and inhibiting the formation of bacterial biofilms. In vivo experiments demonstrated inhibition of MRSA biofilm formation through the encapsulation of TA within fibrin and its sustained release, followed by the sequential release of Van and Cu2⁺ to directly eradicate MRSA. Moreover, Van@CuTA effectively promoted cell proliferation and bone formation. Van@CuTA is a multifunctional system that integrates biofilm targeting, drug release, antimicrobial activity, and cuproptosis-like bacterial death.
CONCLUSION: This study offers a novel and promising strategy for the development of antimicrobial agents to combat MRSA-induced chronic osteomyelitis.